Echinacea Safety Study

Phase 4

Completed

• Conditions: Infections
• Interventions: Drug: placebo; Drug: echinacea

• Registration Number: NCT01021995
• Lead Sponsor: A. Vogel AG

Brief Summary

Extracts produced from Echinacea purpurea are traditionally used for the prevention and the acute treatment of influenzal infections like the common cold. The aim of this clinical study is to assess clinical safety and efficacy of a treatment with Echinacea in comparison to placebo. 750 healthy subjects with a history of equal or more than 2 cold episodes per year will be recruited during October and November 2009 and will be treated with either Echinacea or placebo over a period of 4 months.

Throughout the study period adverse events (AEs) and adverse drug reactions (AEs with at least a possible causal relation to the treatment) will be recorded.

Common cold related symptoms will be recorded in a daily diary.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10
• Study First Submitted: 2009-11-30
• Study First Submitted QC: 2009-11-30
• Study First Posted: 2009-12-01
• Primary Completion: 2010-08
• Study Completion: 2011-04
• Status Verified: 2011-06
• Last Update Submitted: 2014-07-22
• Last Update Posted: 2014-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 757

Inclusion Criteria

• On average more than 2 cold episodes per year
• Age above 18 years
• Good physical condition
• Signed informed consent

Exclusion Criteria

• Women without appropriate and effective contraception
• Participation in a clinical trial 30 days prior to this trial
• Pregnant or breast feeding women
• Subjects with pre-existing cold symptoms for more than 24h at inclusion
• Concurrent participation in another clinical trial
• Intake of antimicrobial and/or antiviral medications at inclusion
• Alcohol and/or drug abuse, narcotic drug addiction before and during trial (more than 50 gr and / or 10 cigarettes per day)
• Psychiatric disorders which may influence the results of the trial,
• epilepsy, suicide attempts
• Planned surgical intervention during the trial.
• Serious chronic diseases which influence the absorption, metabolism and the elimination of the investigational product, especially progressive systemic illnesses like tuberculosis, leukaemia,
• collagen disorders and multiple sclerosis
• Known AIDS, HIV-infections and autoimmune diseases
• Known diabetes mellitus (type 1)
• Corticosteroid-treated asthma
• Atopic and allergic subjects (under medicinal treatment)
• Known allergy to plants of the composite family (Asteraceae)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	placebo	-
echinacea	echinacea	-

Primary Outcome Measures

Name	Time	Method
Occurrence of Adverse Drug Reactions	4 months

Secondary Outcome Measures

Name	Time	Method
efficacy	4 months

Trial Locations

Locations (1)

Cardiff School of Biosciences; 🇬🇧 Cardiff, Wales, United Kingdom